Nautilus Biotechnology (NASDAQ:NAUT) Trading Up 0.8% – Here’s Why

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price traded up 0.8% during trading on Friday . The stock traded as high as $2.50 and last traded at $2.40. 108,352 shares changed hands during mid-day trading, an increase of 37% from the average session volume of 79,021 shares. The stock had previously closed at $2.38.

Nautilus Biotechnology Price Performance

The firm has a market cap of $301.35 million, a price-to-earnings ratio of -4.29 and a beta of 1.23. The company’s 50 day simple moving average is $2.70 and its 200 day simple moving average is $2.61.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period in the previous year, the company posted ($0.13) EPS. As a group, analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Mary E. Godwin sold 35,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total value of $99,750.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 40.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NAUT. Price T Rowe Associates Inc. MD lifted its stake in Nautilus Biotechnology by 35.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after purchasing an additional 4,239 shares during the last quarter. SG Americas Securities LLC purchased a new position in Nautilus Biotechnology in the third quarter valued at approximately $50,000. The Manufacturers Life Insurance Company acquired a new stake in Nautilus Biotechnology during the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Nautilus Biotechnology by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after buying an additional 9,404 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of Nautilus Biotechnology in the 3rd quarter valued at $87,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.